Efficacy of entecavir alone and combined with probiotics in the treatment of hepatitis B cirrhosis and analysis of safety
10.3760/cma.j.cn115455-20231121-00488
- VernacularTitle:恩替卡韦单药与联合益生菌治疗乙型肝炎肝硬化的疗效及安全性分析
- Author:
Yan WANG
1
;
Chengtao FU
;
Jian WANG
;
Yuanzheng GAO
Author Information
1. 滨州市中心医院感染性疾病科，滨州 251700
- Publication Type:Journal Article
- Keywords:
Hepatitis B;
Liver cirrhosis;
Entecavir;
Probiotics
- From:
Chinese Journal of Postgraduates of Medicine
2025;48(4):365-369
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analysis of the efficacy and safety of entecavir monotherapy and entecavir combined with probiotic therapy in the treatment of hepatitis B cirrhosis.Methods:A total of 88 patients with hepatitis B cirrhosis diagnosed and treated in Binzhou Central Hospital from May 2020 to May 2022 were prospectively selected as the study objects, and divided into the control group (44 cases) and the observation group (44 cases) according to random number table method. The control group was given entecavir monotherapy, and the observation group was given entecavir combined with probiotics. The levels of intestinal flora, blood ammonia (BUN), liver function index and liver fibrosis were compared between the two groups before and after treatment, and the clinical efficacy after 3 months of treatment and the occurrence of adverse reactions during treatment were compared between the two groups.Results:After treatment, the ratio of harmful/beneficial bacteria, serum BUN, total bilirubin (TBIL), alanine aminotransferase (ALT), azelaic aminotransferase (AST), glutamyltransferase (GGT), pre-collagen type Ⅲ(PCⅢ), collagen type Ⅳ (Ⅳ-C), laminin (LN), and hyaluronidase (HA) in the observation group were lower than those in the control group: (10.52 ± 1.35)% vs. (11.38 ± 2.19)%, (70.26 ± 6.94) μmol/L vs. (76.34 ± 10.59) μmol/L, (32.76 ± 4.27) μmol/L vs. (36.82 ± 6.41) μmol/L, (51.82 ± 6.37) U/L vs. (56.34 ± 5.74) U/L, (37.83 ± 5.61) U/L vs. (42.75 ± 12.89) U/L, (42.67 ± 11.84) U/L vs. (48.16 ± 13.49) U/L, (118.76 ± 23.65) μg/L vs. (129.24 ± 21.16) μg/L, (74.34 ± 17.58) μg/L vs.(82.39 ± 20.05) μg/L, (127.65 ± 12.23) mg/L vs. (138.97 ± 11.76) mg/L, (107.78 ± 23.47) mg/L vs. (119.65 ± 22.35) mg/L, there were statistical differences ( P<0.05). During the 3-month treatment period, the total effective rate in the observation group was higher than that in the control group and the total incidence of adverse reactions was lower than that in the control group: 88.64%(39/44) vs. 70.45%(31/44), 4.55%(2/44) vs. 18.18%(8/44), there were statistical differences ( χ2 = 4.47, 4.06, P<0.05). Conclusions:In the treatment of hepatitis B cirrhosis patients, entecavir combined with probiotics can effectively regulate gastrointestinal function, reduce BUN level, and then more conductive to liver function recovery, reduce the process of liver fibrosis, improve efficacy, and reduce the occurrence of adverse reactions.
